CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.

ABSTRACT: Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor specificity and the postulated toxicities of CART-133 were first assessed. Then, we conducted a phase I clinical study in which patients with advanced and CD133-positive tumors received CART-133 cell-infusion. We enrolled 23 patients (14 with hepatocellular carcinoma [HCC], 7 with pancreatic carcinomas, and 2 with colorectal carcinomas). The 8 initially enrolled patients with HCC were treated by a CART-133 cell dose escalation scheme (0.05-2 × 10⁶/kg). The higher CAR-copy numbers and its reverse relationship with the count of CD133+ ce

SUBMITTER: Wang Y 

PROVIDER: S-EPMC5993480 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature